Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review

Oral Oncology Reports Pub Date : 2024-07-11 DOI:10.1016/j.oor.2024.100596

Abdulrahman Hesham, Fawaz AlOtaibi, D. David Kim, Yousef Alshamrani, Joao Hyppolito, Katie Jubala

{"title":"Neoadjuvant pembrolizumab-carboplatin-paclitaxel in locally advanced squamous cell carcinoma of the oral cavity: A case report and literature review","authors":"Abdulrahman Hesham, Fawaz AlOtaibi, D. David Kim, Yousef Alshamrani, Joao Hyppolito, Katie Jubala","doi":"10.1016/j.oor.2024.100596","DOIUrl":null,"url":null,"abstract":"<div><p>Head and neck cancers are being diagnosed more frequently in elderly patients and at advanced stages. In these cases, standard treatment methods are often not feasible due to patient frailty and malnutrition. A few trials have demonstrated the safety and effectiveness of immune checkpoint inhibitors (ICIs) as neoadjuvant therapy for locally advanced oral cancer. We present the case of a 51-year-old male patient who had locally advanced oral cavity cancer that was treated with the combination of pembrolizumab and weekly carboplatin and paclitaxel. This treatment resulted in a major pathological response, leading to a significant reduction in tumor size and allowing for surgical treatment. In addition, the patient remains free of locoregional disease nine months after the surgery<strong>.</strong> Clinical trials are essential to investigate the viability of this potentially less toxic and more convenient combined therapy in patients with advanced squamous cell carcinoma of the oral cavity.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"11 ","pages":"Article 100596"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004424/pdfft?md5=276b00cf6cd0c17dc8aaa091826f303f&pid=1-s2.0-S2772906024004424-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772906024004424","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Head and neck cancers are being diagnosed more frequently in elderly patients and at advanced stages. In these cases, standard treatment methods are often not feasible due to patient frailty and malnutrition. A few trials have demonstrated the safety and effectiveness of immune checkpoint inhibitors (ICIs) as neoadjuvant therapy for locally advanced oral cancer. We present the case of a 51-year-old male patient who had locally advanced oral cavity cancer that was treated with the combination of pembrolizumab and weekly carboplatin and paclitaxel. This treatment resulted in a major pathological response, leading to a significant reduction in tumor size and allowing for surgical treatment. In addition, the patient remains free of locoregional disease nine months after the surgery. Clinical trials are essential to investigate the viability of this potentially less toxic and more convenient combined therapy in patients with advanced squamous cell carcinoma of the oral cavity.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新辅助帕姆单抗-卡铂-紫杉醇治疗局部晚期口腔鳞状细胞癌：病例报告和文献综述

头颈部癌症越来越多地在老年患者和晚期患者中确诊。在这些病例中，由于患者体弱和营养不良，标准治疗方法往往不可行。一些试验证明，免疫检查点抑制剂（ICIs）作为局部晚期口腔癌的新辅助治疗具有安全性和有效性。我们介绍了一例 51 岁男性患者的病例，他患有局部晚期口腔癌，接受了 pembrolizumab 与每周卡铂和紫杉醇的联合治疗。这种治疗方法产生了重大的病理反应，导致肿瘤体积显著缩小，并使手术治疗成为可能。此外，患者在手术九个月后仍未出现局部病变。临床试验对于研究这种可能毒性更小、更方便的联合疗法在口腔晚期鳞状细胞癌患者中的可行性至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oral Oncology Reports

CiteScore

0.20

自引率

0.00%

发文量